✕

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.

Share

Office of the Chief Medical Officer

he Johnson & Johnson Office of the Chief Medical Officer (OCMO) is a global, functionally independent group responsible for leading safety and championing bioethical principles across Johnson & Johnson’s Pharmaceutical, Medical Device and Consumer Health sectors. Johnson & Johnson’s OCMO is constantly reviewing, monitoring and making decisions regarding the safety of our products through people-driven processes, initiatives and policies that are reinforced by a single medical safety standard, to which all our products are held.

OCMO

Watch the Video

Scientific Excellence, Bioethics and Values-Driven Decision-Making

Scientific Excellence, Bioethics and Values-Driven Decision-Making

Learn More

Expanding Access to Our Investigational Medications

Expanding Access to Our Investigational Medications

Learn More

Engaging with Patients & Consumers as Partners

Engaging with Patients & Consumers as Partners

Learn More

Making Healthcare Decisions Through a Bioethical Lens

Making Healthcare Decisions Through a Bioethical Lens

Learn More

Innovating to Advance Health Outcomes for Patients & Consumers

Innovating to Advance Health Outcomes for Patients & Consumers

Our Ethics- and Science-Driven Healthcare Initiatives

OCMO Safety

Safety Assessment of Johnson & Johnson Products

Safety Assessment of Johnson & Johnson Products

Within Johnson & Johnson’s Office of the Chief Medical Officer, safety assessment that is objective and science- and evidence-based is at the core of what we do and is built into every stage of our products’ life cycles—from development to post-launch. But just how do we do it?

The Power of Real-World Data to Enhance Safety

The Power of Real-World Data to Enhance Safety

The Power of Real-World Data to Enhance Safety

The Johnson & Johnson Office of the Chief Medical Officer (OCMO) believes in the collective power of real-world observational data to complement clinical trial findings, and in sharing our insights widely to accelerate important research and policy developments and improve health outcomes for people everywhere.

A photo of test tubes and pipettes

The Yale Open Data Access Project

The Yale Open Data Access Project

Sharing of clinical trial data is critical to the advancement of the science that is the foundation of medicine and public health. It furthers our understanding of diseases, expands the base of knowledge needed to develop new treatments and generates new insights and more complete evidence to enable better healthcare decisions for patients.

A photo of doctors talking about bioethics

Decisions Guided Through a Bioethical Lens

Decisions Guided Through a Bioethical Lens

Bioethics is an applied discipline that takes the principles of ethics and applies them to biological research, science and medicine. Adherence to bioethical principles, including transparency, integrity and respect for the rights and welfare of all persons, stems from Our Credo values and the commitment we make to our patients and consumers.

A photo of a child receiving a vaccination in their right arm

Compassionate Use

Compassionate Use

A photo of a mother and her son laughing

CHILD: A Commitment to Children and Parents

CHILD: A Commitment to Children and Parents

Our commitment to the safety and well-being of children has been a cornerstone of Johnson & Johnson's work for over 130 years, and we are committed to continue improving medical innovation for children.

Featured

Every day, we work to put people first—from proactive and transparent medical safety surveillance, to groundbreaking real-world evidence applications, pediatric clinical research advancements, early access innovation and more.

Newborn baby being treated in hospital

Office of the Chief Medical Officer

Why Johnson & Johnson Is on a Mission to Make Treating Pediatric Patients Safer

Why Johnson & Johnson Is on a Mission to Make Treating Pediatric Patients Safer

For Baby Safety Month, we sat down with the company's Head of Pediatric Drug Development to learn about its industry-leading Child Health Innovation Leadership Department.

Read the Story

A photo of Gary Eichenbaum

Office of the Chief Medical Officer

Preclinical Science: Driving Excellence in Safety at Johnson & Johnson

Preclinical Science: Driving Excellence in Safety at Johnson & Johnson

A Q&A with Gary Eichenbaum, Ph.D., Vice President, Preclinical Science and Safety, Office of the Chief Medical Officer, Johnson & Johnson.

Read the Story

A photo of Joanne Waldstreicher — Joanne Waldstreicher, M.D., Chief Medical Officer, Johnson & Johnson

Office of the Chief Medical Officer

How Johnson & Johnson Is Helping Patients Through Its Compassionate Use Program

How Johnson & Johnson Is Helping Patients Through Its Compassionate Use Program

The company's mission is to care for the world—one person at a time. Just ask Chief Medical Officer Joanne Waldstreicher, M.D., who's been leading the charge to improve the process by which very sick patients may apply for access to investigational medications.

Learn More

Johnson & Johnson Chief Medical Officers

Our Chief Medical Officers drive medical safety excellence and innovation across our Pharmaceuticals, Medical Devices and Consumer Products sectors.

Joanne Waldstreicher bio image_circle — Joanne Waldstreicher, M.D., Chief Medical Officer

Aran Maree, M.D., Chief Medical Officer, Pharmaceuticals

Jijo James, M.D. — Jijo James, M.D., Chief Medical Officer, Medical Devices

Ed Kuffner, M.D., Chief Medical Officer, Consumer

In the News

News and highlights about the Office of the Chief Medical Officer.

A photo of a person typing on a computer keyboard

Bioethics

How the Industry Is Addressing the Ethical Concerns of Incorporating Big Data into Health Care

How the Industry Is Addressing the Ethical Concerns of Incorporating Big Data into Health Care

Clinical Trials

Overview and Experience of the YODA Project With Clinical Trial Data Sharing After 5 Years

Overview and Experience of the YODA Project With Clinical Trial Data Sharing After 5 Years

Innovation

How Women at Johnson & Johnson Are Changing Healthcare As We Know It

How Women at Johnson & Johnson Are Changing Healthcare As We Know It

Compassionate Use

Johnson & Johnson Expands Access to Investigational Medications Through Its CompAC Program

Johnson & Johnson Expands Access to Investigational Medications Through Its CompAC Program

Innovation

The Yale Open Data Access Project: How Johnson & Johnson Is Leading the Way on Clinical Data Transparency

The Yale Open Data Access Project: How Johnson & Johnson Is Leading the Way on Clinical Data Transparency

Research team

Bioethics

New York Times: Company Creates Bioethics Panel on Trial Drugs

New York Times: Company Creates Bioethics Panel on Trial Drugs

Read More News

Scientific Policies

Johnson & Johnson is committed to ethical decision-making and transparency to guide every decision we make. Read more for our scientific policies on sensitive topics.

Position on Human Pluripotent Stem Cell Research

June 11, 2020

These guidelines are to ensure that human pluripotent stem cell research conducted by Johnson & Johnson conforms to current international standards of scientific and ethical oversight, and that all scientists and employees of the Johnson & Johnson Family of Companies adhere to these ethical principles when conducting human pluripotent stem cell research.

Learn More
Ethical Code for the Conduct of Research and Development

June 11, 2020

Our Ethical Code for the Conduct of Research and Development is intended to complement our Credo by providing more specific standards of conduct and behavior for physicians, clinical research scientists and others who are responsible for medical aspects of research and development.

Learn More
Position on Clinical Trial Data Transparency

June 11, 2020

We believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our pharmaceutical products and providers who prescribe them.

Learn More
Position on Compassionate Use & Pre-Approval Access

June 11, 2020

We follow five important principles when providing pre-approval access to investigational medicines to patients with serious diseases to access medicines not yet approved by regulatory health authorities.

Learn More

5 Ways We're Helping Build a World of Well

Learn more about how we're helping build a world of well through efforts in five key areas of healthcare.

Read More About This Work

More From Johnson & Johnson

Jennefer Wetzel, Ganendra Awang Kristandya, Zolelwa Sifumba, M.D., and Saurabh Rane are working to end TB

Personal Stories

“We Want a World Without Tuberculosis in Our Lifetimes”

“We Want a World Without Tuberculosis in Our Lifetimes”

Healthcare providers who contracted TB on the job. A microbiologist researching new treatments. An activist ensuring attention is paid to one of the world’s greatest health threats. These young leaders share one goal: to help end TB.

An infographic showing a variety of women in different types of clothes, with text about 9 ways Johnson & Johnson has supported women

Caring & Giving

9 Ways Johnson & Johnson Has Supported Women Since 1886

9 Ways Johnson & Johnson Has Supported Women Since 1886

Learn how the world's largest and most broadly based healthcare company has been empowering female employees, scientists and leaders—and improving the well-being of mothers around the world—since its founding 136 years ago.

Flooded rural area impacted by climate change

Health & Wellness

4 Questions About the Health Impacts of Climate Change

4 Questions About the Health Impacts of Climate Change

Johnson & Johnson is launching a new collaboration to advance health equity by building climate resilience in U.S. medical clinics that face floods, fires, heat waves and more. This initiative is just one of the ways the company is working to bolster healthcare in communities that are disproportionately impacted by climate change. Learn more from the company’s Chief Sustainability Officer.